AI-designed drugs to hit market within five to six years, Insilico CEO predicts

BOSTON, MASSACHUSETTS: The first drugs conceived entirely by artificial intelligence will likely be commercially available around the end of the decade, according to the leader of an AI drug discovery startup.

“I would be surprised if we do not see it over the next five to six years,” Alex Zhavoronkov, CEO of Insilico Medicine, said in an interview. “I hope we will be the first ones – we have more than 40 programmes internally – but you never know.”

The pharmaceutical industry has long touted the promise of AI in slashing time and costs in the research and development process, although none has been approved so far. Takeda Pharmaceutical Co. is in final clinical testing of a psoriasis drug selected by AI, with data expected this year.

Ottimo raises $140 million in pursuit of ‘$100 billion market’ for new cancer drugs

While most companies, according to Zhavoronkov, currently use AI in a piecemeal manner, what sets Insilico apart is his assessment is that it incorporates the technology in every step from target hypothesis to drug optimisation to deliver drugs ready for human trials.

Insilico, which has operations across the US, China, the Middle East and Canada, recently filed anew for a listing on the Hong Kong stock exchange, after raising a private round that valued the company at more than $1 billion.